Agenus Inc. (AGEN)
$
4.18
-0.07 (-1.67%)
Key metrics
Financial statements
Free cash flow per share
-4.5297
Market cap
133.2 Million
Price to sales ratio
1.3096
Debt to equity
-1.1358
Current ratio
0.0569
Income quality
0.7357
Average inventory
0
ROE
0.5964
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agenus Inc., a clinical-stage immuno-oncology company operating in the United States and internationally, is focused on discovering and developing innovative immuno-oncology products. The company's operating income ratio is -1.16 indicating the company's operational profitability margin. Additionally, the gross profit ratio is -0.51 reflecting the efficiency of the company's production and sales operations. Agenus Inc. leverages its Retrocyte Display, an advanced antibody expression platform, for identifying fully human and humanized monoclonal antibodies. The organization also develops various vaccine programs, including the Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Its product pipeline features several promising candidates, such as Balstilimab, an anti-PD-1 antagonist that has completed a Phase II clinical trial for second line cervical cancer, AGEN1181, an anti-CTLA-4 monospecific antibody currently in Phase 1/2 clinical trial, and AGEN2373, an anti-CD137 monospecific antibody in Phase 1 clinical trial. Other notable developments include AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has finished its Phase 1 clinical trial, and AGEN1777, an anti-TIGIT bispecific antibody. Furthermore, AGEN1327 is a human monoclonal antibody, while INCAGN1876, INCAGN1949, INCAGN2390, and INCAGN2385 are specialized anti-GITR, anti-OX40, anti-TIM-3, and anti-LAG-3 monoclonal antibodies, respectively. The company also has ARDS-targeting AGENT 797 in Phase 1 clinical trials, and AGEN1884, a first-generation anti-CTLA-4 antibody. Agenus collaborates with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. was formerly known as Antigenics Inc. and rebranded in January 2011. The company reported depreciation and amortization expenses of $13,343,000.00 reflecting the wear and tear of its assets. The EBITDA is -$101,302,000.00 a key indicator of the company's operational profitability. The financial data pertains to the fiscal year 2024. As a small-cap player with a market capitalization of $133,191,938.00 Agenus controls a pivotal role in the Biotechnology industry, making significant contributions to the overall market landscape. The stock is affordable at $6.83 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 1,180,415.00 indicating lower market activity. The company belongs to the Healthcare sector, driving innovation and growth within the evolving landscape of immuno-oncology.
Is Agenus Inc. (AGEN) a good investment?
Investing in Agenus Inc. (AGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Agenus Inc. (AGEN)'s stock forecast?
Analysts predict Agenus Inc. stock to fluctuate between $1.38 (low) and $7.34 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agenus Inc.'s market capitalization?
As of 2025-08-29, Agenus Inc.'s market cap is $133,191,938, based on 31,864,100 outstanding shares.
How does Agenus Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agenus Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agenus Inc. (AGEN) stock?
To buy Agenus Inc. (AGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGEN. Place an order (Market, Limit, etc.).
What is the best time to invest in Agenus Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Agenus Inc. stock ever split?
Agenus Inc.'s last stock split was 1:20 on 2024-04-12.
How did Agenus Inc. perform in the last earnings report?
Revenue: $103,463,000 | EPS: -$10.59 | Growth: -22.98%.
Where can I find Agenus Inc.'s investor relations reports?
Visit https://www.agenusbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agenus Inc.?
You can explore historical data from here
What is the all-time high and low for Agenus Inc. stock?
All-time high: $135.80 (2021-08-30) | All-time low: $1.38 (2025-04-07).
What are the key trends affecting Agenus Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET which introduces a new virtual format to provide an engaging experience for attendees, along with an updated participation link. Stakeholder Webcast Participation Details NEW Audience Webcast Link | https://riverside.fm/studio/agenus-presentation Pre-registration is not required. The program will c.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ColorectalCancer--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnersh.
zacks.com
Agenus (AGEN) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $2.52 per share a year ago.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a next-generation, multifunctional, Fc enhanced, CTLA-4 antibody and BAL is a proprietary PD-1 antibody; t.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive update on the global botensilimab (BOT) and balstilimab (BAL) development program. About Agenus Agenus is a leading im.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17-21. The highlight is an oral presentation that will feature emerging survival plateaus from a study of botensilimab plus balst.
zacks.com
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.
zacks.com
After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
See all news
